In addition, the use of spironolactone (HR: 0.664; 95% CI: 0.522–0.846; p = 0.004), use of β-blocker, ACEIs/ABRs or statins, age, gender, heart rate, Ln alanine aminotransferase, Ln aspartate aminotransferase, CKD stage, low-density lipoprotein cholesterol, LnBNP, D-dimer, hemoglobin, potassium, history of diabetes, smoking, alcohol use, coronary heart disease and LVEF. This evidence concerns the gene GPT and chronic kidney disease.